Press Release: Opentrons Announces $200 Million Series C Financing Led by SoftBank

Opentrons will use the funding to expand its automated laboratory platform for life sciences and healthcare.

New York, NY – September 23, 2021: Today Opentrons Labworks Inc. announced that SoftBank Vision Fund 2* has led a $200 million Series C investment in the company, with participation from Khosla Ventures. Opentrons will use the funding to further invest in its global automated laboratory platform.

"Biology opens the door to solving many of humanity's grand challenges. For too long, scientists and clinicians have been hamstrung by the slow, expensive, and overly complex laboratory solutions that underpinned their work." Opentrons CEO Jon Brennan-Badal said. "Opentrons' platform provides the key to unlocking its potential. We are doing more R&D, more testing, more biological research to unlock innovation in life sciences and healthcare."

This laboratory platform uniquely integrates the development of laboratory robotics, analysis and operations to create high-quality and cost-effective end solutions. Opentrons uses the platform to provide the following industry-specific laboratory solutions:

• Health System Diagnostic Laboratory Services：通过子公司流行病应对实验室，该公司将该平台用于自己的子公司实验室，提供价格低廉、高通量的分子诊断测试。 去年，美国各地的医院和卫生系统已使用这些检测实验室服务对超过 450 万名患者进行了检测。
• Laboratory automation robots for life science R&D：通过 Opentrons Robotics 业务部门，该公司销售价格实惠的实验室机器人，以帮助生命科学研发实验室实现操作自动化。 Opentrons 的旗舰产品 OT-2 机器人被 40 多个国家的数千个研究组织使用。 在整个 COVID-19 大流行期间，OT-2 机器人被部署到世界各地的医院实验室来测试数百万患者样本。
• Genome-scale cell engineering for biopharmaceuticals：通过 Neochromosome 子公司，该公司开发并部署了其生物铸造厂，该工厂具有独特的能力，能够以前所未有的通量合成基因组规模的 DNA 构建体。 利用最近收购的 Zenith AI 的合作，该公司正在为治疗药物的发现、开发和生物制造创造变革性解决方案。

"Opentrons is building a disruptive automated laboratory platform designed to transform healthcare and life sciences with vertically integrated, low-cost solutions," said Angela Du, investment director at SoftBank Investment Advisors. "The company has expertise in laboratory diagnostics and synthesis The genomics market has a strong value proposition and its robotics and consumables are now fundamental components of the market. We look forward to working with CEO Jonathan Brennan-Badal to help the company accelerate growth and commercialize new products."

The Series C round will bring significant investment into the Opentrons platform. In particular, the investment will support the development of new robotic tools, an expanded biofoundry, new diagnostic tests and additional diagnostic laboratories. All of these initiatives will lead to better, more affordable solutions for our life sciences and healthcare customers.

OPENTRONS announces the addition of key teams to the Scale platform:

• Myrtle Potter, Opentrons Labworks, Inc. 董事会主席。Myrtle 现任 Sumitovant 首席执行官。 前身为 Roivant Sciences、Genentech、BMS、Merck。
• Greg Greeley, Opentrons Labworks, Inc. 总裁兼首席运营官。Greg 曾任 Airbnb 总裁、亚马逊欧洲业务副总裁，并领导亚马逊全球 Prime 计划。 Greg 将加入 Opentrons 董事会。
• Roberts. Langer, Neochromosome, Inc. 科学顾问委员会主席。麻省理工学院研究所教授。 Moderna 联合创始人。
• JE FBO ECan, PRL 科学顾问委员会主席、Sol 和 Judith Bergstein 系统遗传学研究所所长、纽约大学朗格尼分校生物化学和分子药理学系教授。 PRL 和 Neochromosome 的联合创始人。

About OPENTRONS LABWORKS INC., SUBSIDIARIES AND INVESTORS

• openSame as Ron slab works Inc.Opentrons 开发综合实验室平台，通过 Opentrons Robotics、Pandemic Response Lab 和 Neochromosome 子公司为生命科学和医疗保健客户提供服务。
• open TR ONS robotics是 Opentrons Labworks Inc 的一个业务部门，是灵活、用户友好的实验室自动化领域的行业领导者。 Opentrons Robotics 的旗舰产品 OT-2 遍布 40 多个国家的数千个实验室。 这些机器人可以在以下位置购买：https://opentrons.com/
• pandemic response lab (PRL) 是 Opentrons Labworks Inc. 的全资子公司，该公司利用该平台为美国各地的卫生系统提供诊断实验室服务。 您可以访问 https://pandemicresponselab.com/ 了解有关 PRL 诊断实验室服务产品的更多信息
• neochromosome (neo) 是 Opentrons 于 2021 年 3 月收购的全资子公司。Neo 利用 Opentrons 平台创建用于治疗的基因组规模细胞工程解决方案。 您可以访问 https://neochromosome.com/ 了解有关 Neo 基因组规模细胞工程解决方案的更多信息
• zenith AI是 Opentrons 于 2021 年 6 月收购的全资子公司。Zenith AI 为 Opentrons 平台带来了专有的无代码人工智能和现代机器学习。 您可以访问 https://www.zenify.ai/ 了解有关 Zenith AI 的更多信息
• SoftBank Investment Advisors, Inc. (SBIA)是软银集团的一部分，软银集团是一家总部位于东京港区的日本跨国集团控股公司。 SBIA 是愿景基金的管理人，该基金寻求通过投资市场领先的企业来加速人工智能革命。
• open TR ONS的其他投资者包括 Sands Capital、Lerer Hippeau Ventures、SOSV 和 Y Combinator。